Methodological considerations for interpreting ketamine-naltrexone trials in depression
Int J Neuropsychopharmacol
.
2025 Oct 1;28(10):pyaf073.
doi: 10.1093/ijnp/pyaf073.
Authors
Igor D Bandeira
1
,
Luke A Jelen
2
3
,
Jason M Tucciarone
1
,
Boris D Heifets
1
4
,
Carolyn I Rodriguez
1
,
Alan F Schatzberg
1
Affiliations
1
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States.
2
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
3
South London and Maudsley NHS Foundation Trust, London, United Kingdom.
4
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, United States.
PMID:
41036664
PMCID:
PMC12530182
DOI:
10.1093/ijnp/pyaf073
No abstract available